| Website | pharmathene.com |
| Category | BioTech |
| Phone | 410-269-2600 |
| stacey.jurchison@... | |
| Employees | |
| Founded | 2001 |
| Description | biotechnology company |
| TOTAL | $19.3M |
| FUNDING TOTAL | $19.3M |
| Venture Round, 7/09 HealthCare Ventures MPM Capital Baker Brothers Investments Ontario Teachers Pension Plan | $19.3M |
PharmAthene, Inc., a biodefense company, develops medical countermeasures to prevent and treat morbidity and mortality associated with the use of biological and chemical weapons in the United States. Its products, which are under development, include Valortim, a prophylactic and therapeutic anti-anthrax monoclonal antibody; and Protexia, a recombinant form of human butyrylcholinesterase for clinical use in the treatment of organophosphate intoxication due to exposure to chemical nerve agents. The company was founded in 2001 and is headquartered in Annapolis, Maryland.
